Application of N-lactylphenylalanine and N-acetyltaurine in preparation of multifunctional therapeutic drugs

By studying the pharmacological effects of the endogenous molecules Lac-Phe and N-acetyltaurine, the problems in the existing technology that failed to effectively prevent and treat altitude sickness, hypoxemia, etc. were solved, and the oral administration was adopted to achieve Improve anti-hypoxia ability, reduce uric acid levels, anti-drug liver damage, whitening and freckle removal, and other effects provide new treatment methods.

CN119074711APending Publication Date: 2024-12-06GUANGDONG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411436598.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing technology has not effectively explored the effects of oral administration of N-lactylphenylalanine (Lac-Phe) and N-acetyltaurine on the physiological function of the body, and lacks the prevention and treatment of altitude sickness, hypoxemia, and respiratory Drug applications in failure, drug-induced liver injury, hyperuricemia, whitening and freckle removal and anti-fatigue.

Method used

Through research, the pharmacological effects of endogenous molecules Lac-Phe and N-acetyltaurine were discovered, and it was proposed to prevent and treat altitude sickness, hypoxemia, respiratory failure, drug-induced liver injury, hyperuricemia, whitening and freckle removal and anti-epidemic disease, hypoxemia, and New uses for fatigue and other aspects, use oral preparations or other preparations for administration to improve the quality of life of patients.

Benefits of technology

Lac-Phe and N-acetyltaurine significantly improve the anti-hypoxia ability in normal and low-pressure hypoxia environments, reduce blood uric acid levels, resist alcoholism, improve drug-induced liver damage, and have whitening and freckle removal and fatigue resistance. Effects provide new treatment methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074711A_ABST
    Figure CN119074711A_ABST
Patent Text Reader

Abstract

The invention relates to novel medicinal application of N-lactylphenylalanine (Lacc-Phe) and N-acetyltaurine, and belongs to the technical field of medicines. The application of the Lacc-Phe and the N-acetyltaurine in preparation of drugs / health care products for preventing and treating altitude sickness, hypoxemia, respiratory failure, drug-induced liver injury and hyperuricemia, whitening and removing freckles, resisting fatigue and the like is found for the first time, and the Lacc-Phe and the N-acetyltaurine have wide development prospects. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to new medicinal uses of N-lactylphenylalanine (Lac-Phe) and N-acetyltaurine, and belongs to the technical field of medicine. Background Art

[0002] Endogenous active ingredients in the human body often have the advantages of clear efficacy and low toxic side effects, and have great potential for development into therapeutic drugs and health products. Recent studies have found that an endogenous small molecule N-lactylphenylalanine (Lac-Phe) is produced in the blood during strenuous exercise, which can effectively reduce food intake and thus control obesity (Nature, 2022, 606, 785-790). However, there are currently few studies on Lac-Phe, and they are limited to the research conducted through injection in the above-mentioned studies. There is no relevant research on the effects of oral administration on the physiological functions of the body.

[0003] N-acetyltaurine is an endogenous taurine derivative, and its content in biological fluids is regulated by a variety of physiological processes, including aerobic exercise, alcohol intake, and taurine dietary supplementation. In addition, the chemical structure of N-acetyltaurine is similar to known signaling molecules (such as the neurotransmitter acetylcholine and long-chain N-acyltaurine), suggesting that it may also function as a signaling molecule. Current studies have shown that N-acetyltaurine has important physiological functions in inhibiting eating and resisting obesity (Nature, 2024, DOI: 10.1038 / s41586-024-07801-6), however, other potential physiological functions of acetyltaurine remain unsolved mysteries.

[0004] The present invention is the first to deeply explore the pharmacological effects of oral administration of Lac-Phe and N-acetyltaurine, expand their medicinal / health product functions, and is highly innovative and has broad application prospects. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide two non-toxic and safe drugs that can prevent and treat symptoms related to altitude sickness, hypoxemia, respiratory failure, alcohol poisoning, drug-induced liver injury, hyperuricemia, gout, whitening and freckle removal, and anti-fatigue.

[0006] The inventors have found through research that endogenous molecules Lac-Phe (N-lactylphenylalanine) and N-acetyltaurine can improve the ability to resist hypoxia in normal pressure and low pressure hypoxic environments, the survival rate of alcohol poisoning, improve drug-induced liver damage, resist hyperuricemia, whiten and remove spots, and resist fatigue. Therefore, Lac-Phe and N-acetyltaurine have broad application prospects in preventing and treating altitude sickness, hypoxemia, respiratory failure, drug-induced liver damage, hyperuricemia, whiten and remove spots, and resist fatigue, and can improve the quality of life of patients.

[0007] Based on a large number of studies, the present invention proposes the use of Lac-Phe and N-acetyltaurine in the preparation of drugs for preventing and treating altitude sickness, hypoxemia, respiratory failure, drug-induced liver injury, hyperuricemia, whitening and anti-freckle, and anti-fatigue. The structures of N-lactylphenylalanine (1) and N-acetyltaurine (2) are as follows:

[0008]

[0009] Among them, preferably, the altitude sickness includes altitude sickness, high altitude pulmonary edema and high altitude coma.

[0010] Among them, preferably, the alcohol poisoning includes acute alcohol poisoning, chronic alcohol poisoning, alcoholic fatty liver disease and alcohol dependence.

[0011] Among them, preferably, the drug-induced liver injury includes liver injury induced by direct drug hepatotoxicity, idiosyncratic hepatotoxicity, and indirect hepatotoxicity.

[0012] Preferably, the drug further comprises a pharmaceutically acceptable carrier or excipient.

[0013] Preferably, the drug is an oral preparation, a skin external preparation or an injection preparation.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] The present invention provides for the first time a new use of endogenous molecules Lac-Phe and N-acetyltaurine for preventing and treating altitude sickness, hypoxemia, respiratory failure, drug-induced liver injury, hyperuricemia, whitening and removing spots, and anti-fatigue. The present invention finds that Lac-Phe and N-acetyltaurine can improve the ability to tolerate hypoxia in normal pressure and low pressure hypoxic environments, reduce blood uric acid levels, resist alcohol poisoning, resist drug-induced liver injury, whiten and remove spots, and resist fatigue. The present invention provides a new treatment method for preventing and treating altitude sickness, hypoxemia, respiratory failure, drug-induced liver injury, hyperuricemia, whitening and removing spots, and anti-fatigue. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 :Efficacy of Lac-Phe and N-acetyltaurine in preventing drug-induced liver injury: (A) serum ALT level; (B) serum AST level, (C) HE-stained liver sections. One-way ANOVA and Tukey's multiple-comparison post hoctest were used for statistical analysis (n=6), *P<0.05, **P<0.01, ***P<0.001, compared with the model group. DETAILED DESCRIPTION

[0017] The present invention will be further described below in conjunction with the examples. It should be noted that the following examples are only for illustration, and are not intended to limit the present invention. Various changes made by those skilled in the art based on the teachings of the present invention should be within the scope of protection of the claims of this application.

[0018] Example 1 Lac·Phe and N-acetyltaurine can improve the hypoxia tolerance of mice in normobaric hypoxia environment

[0019] Five-week-old male Kunming mice were randomly divided into a model group, a Lac·Phe group, and an N-acetyltaurine group, with 6 mice in each group. The model group was given 0.5% sodium carboxymethylcellulose (CMC-Na) by gavage, and the other groups were given Lac·Phe (150 mg / kg) and N-acetyltaurine (150 mg / kg) by gavage, respectively. After 3 consecutive days of administration, the mice were placed in a 125 ml wide-mouth bottle, sealed with a rubber stopper, and the asphyxiation time of the animals was closely observed and recorded. After the experiment was completed, the mice were anesthetized and killed, and the brain tissue of the mice was immediately dissected and placed in a cryopreservation tube, sealed with liquid nitrogen, and placed in a -80°C refrigerator. The content of MDA, SOD, and GSH-Px in the brain tissue was subsequently detected using a kit.

[0020] The results are shown in Tables 1 and 2, which show that N-acetyltaurine can significantly increase the survival time of mice in a closed hypoxic environment, and both Lac·Phe and N-acetyltaurine can significantly increase the content of SOD and GSH-Px in the brain of mice and significantly reduce the content of MDA in brain tissue. This shows that Lac·Phe and N-acetyltaurine can improve the hypoxia tolerance of mice in a normal pressure hypoxia environment.

[0021] Table 1: Duration of animal suffocation

[0022]

[0023] Table 2: Contents of MDA, SOD, and GSH-Px in brain tissue

[0024]

[0025] Example 2 Lac·Phe and N-acetyltaurine can improve the hypoxia tolerance of mice in a hypobaric hypoxic environment (simulating high altitude hypobaric hypoxia conditions)

[0026] Kunming mice were randomly divided into model group, Lac·Phe group and N-acetyltaurine group, 6 mice in each group. The model group was given 0.5% sodium carboxymethylcellulose (CMC-Na) by gavage, and the other groups were given Lac·Phe (150mg / kg) and N-acetyltaurine (150mg / kg) by gavage, respectively. After 3 consecutive days of administration, the mice were placed in a 125ml wide-mouth bottle containing about 5g of soda lime, sealed with a rubber stopper, and the asphyxiation time of the animals was closely observed and recorded. After the experiment was completed, the mice were anesthetized and killed, and the brain tissue of the mice was immediately dissected and placed in a cryopreservation tube, sealed with liquid nitrogen, and placed in a -g0℃ refrigerator. The content of MDA, SOD, and GSH-Px in the brain tissue was subsequently detected using a kit.

[0027] The results are shown in Tables 3 and 4, which show that N-acetyltaurine can significantly increase the survival time of mice in a closed hypoxic environment, and both Lac·Phe and N-acetyltaurine can significantly increase the content of SOD and GSH-Px in brain tissue, and significantly reduce the content of MDA in brain tissue. This shows that Lac·Phe and N-acetyltaurine can improve the hypoxia tolerance of mice in a low-pressure hypoxic environment and can be used for the prevention and treatment of altitude sickness.

[0028] Table 3: Duration of animal suffocation

[0029]

[0030] Table 4: Contents of MDA, SOD, and GSH-Px in brain tissue

[0031]

[0032]

[0033] Example 3 Lac·Phe and N-acetyltaurine have anti-hyperuricemia effects

[0034] Five-week-old male Kunming mice were randomly divided into model group, Lac·Phe group and N-acetyltaurine group, with 6 mice in each group. The animals were given 0.5% sodium carboxymethylcellulose (CMC-Na), Lac·Phe (150mg / kg), N-acetyltaurine (150mg / kg) by gavage at -1h, hypoxanthine 200mg / kg was injected intraperitoneally at 0mm, and potassium oxonate 120mg / kg was injected subcutaneously to establish the model. Blood was collected from the tail tip at 1h, 2h, and 4h after the model was established to measure the blood uric acid level. The results are shown in Table 5, which show that Lac·Phe and N-acetyltaurine have a good effect on lowering blood uric acid.

[0035] Table 5: Blood uric acid levels in mice

[0036]

[0037] Example 4 Lac·Phe and N-acetyltaurine have anti-alcoholism effects

[0038] Kunming mice were randomly divided into model group, Lac·Phe group and N-acetyltaurine group, 10 mice in each group. The animals were given 0.5% sodium carboxymethylcellulose (CMC-Na), Lac·Phe (150mg / kg) and N-acetyltaurine (150mg / kg) by gavage at -1h, and 0.025ml / g of 52% liquor was given to each mouse at 0min. The disappearance of the "righting reflex" of mice was used as the indicator of drunkenness. The number of drunken and dead mice was recorded and the drunkenness rate and mortality rate were calculated. The results are shown in Table 6, indicating that Lac·Phe and N-acetyltaurine have good anti-alcoholism activity.

[0039] Table 6: Intoxication rate and mortality rate of mice

[0040]

[0041] Example 5 Lac·Phe and N-acetyltaurine have anti-acetaminophen-induced drug-induced liver injury

[0042] Kunming mice were randomly divided into a normal group, a Lac·Phe group, and an N-acetyltaurine group, with 6 mice in each group. The normal group and the model group were given 0.5% sodium carboxymethylcellulose (CMC-Na) by gavage, and the other groups were given Lac-Phe (150 mg / kg) and N-acetyltaurine (150 mg / kg) by gavage for 3 days. They were fasted for 12 hours on the third night and had normal drinking water. After fasting, except for the normal group, each mouse was intraperitoneally injected with a 300 mg / kg dose of APAP solution. After 10 hours, 2% sodium pentobarbital (50 mg / kg) was given for intraperitoneal anesthesia. Then, blood was collected through orbital blood sampling. The mice were killed by cervical dislocation and fixed on a mouse stand. The skin, subcutaneous tissue, and peritoneum were cut along the midline of the abdomen in turn to expose the abdominal cavity. The liver tissue was removed, washed with physiological saline, and the liver tissue of the left lobe of appropriate size was uniformly cut and soaked in tissue fixative for fixation. (Take 1×1×0.5cm at 5mm from the edge of the right lobe of the liver 3 The large and small liver tissues were fixed in 4% paraformaldehyde for paraffin embedding and HE staining. The remaining tissues were placed in cryopreservation tubes, sealed with liquid nitrogen, and then stored in a -80℃ refrigerator for later use.

[0043] The experimental results are as attached Figure 1The results showed that: HE pathological sections showed that the model induced liver damage in mice. After Lac·Phe and N-acetyltaurine treatment, liver damage was significantly improved, and compared with the model group, the serum AST and ALT of mice in the N-acetyltaurine group were significantly decreased, indicating that Lac·Phe and N-acetyltaurine had a good liver protective effect (Appendix Figure 1 ).

[0044] Example 6 Lac·Phe and N-acetyltaurine have whitening and freckle-removing effects

[0045] After subculturing the cultured human keratinocytes HaCaT cells, a cell suspension was prepared and inoculated into a 12-well cell culture plate, with 5×10 5 cells. After adding 1 ml of culture medium to each well and incubating for 24 hours, the original culture medium was discarded, and 1 ml of maintenance medium as a negative control and maintenance medium containing 10uM Lac·Phe and N-acetyltaurine were added to each well in turn. After 48 hours of drug action, the supernatant was discarded, and the cells were rinsed twice with a pH 7.0 PBS solution, and 90μl of PBS containing 1% Triton X-100 was added to each well. The cells were ultrasonically broken and shaken in an ice water bath for 5 minutes to dissolve the cells. After preheating at 37°C, 10μl of 1% L-DOPA was added to each well, incubated at 37°C for 1 hour, and the absorbance of each well sample was measured at 490nm on an enzyme reader. The formula for calculating the inhibition rate of tyrosinase synthesis is: Tyrosinase synthesis inhibition rate (%) = (1-average absorbance value of the sample group / average absorbance value of the control group) × 100%.

[0046] After the cultured mouse B16 melanocytes were subcultured, the cell suspension was prepared and inoculated into a 12-well cell culture plate, with 5×10 5 cells. After adding 1 ml of culture medium to each well and cultivating for 24 hours, the original culture medium was discarded, and 1 ml of maintenance medium was added to each well as a negative control, and a maintenance medium containing 10uM Lac·Phe and N-acetyltaurine. After 48 hours of drug action, the supernatant was discarded, and the cells were rinsed twice with a pH 7.0 PBS solution. 0.5 ml of trypsin was added to each well to digest the cells, and 1 ml of culture medium was added to terminate the digestion, and each group of cells was counted separately. The cell suspension was centrifuged and the supernatant was discarded to obtain a precipitate, and then a 1 mol / L NAOH solution containing 10% DMSO was added and shaken for 5 minutes. The absorbance of each well sample was measured at 490 nm on an ELISA reader. The synthesis inhibition rate of melanin was calculated as follows: Synthesis inhibition rate of melanin (%) = [1-(absorbance value of sample well / number of cells in sample well) / (absorbance value of control well / number of cells in control well)] × 100%. The results are shown in Table 7, which indicate that Lac·Phe and N-acetyltaurine have good whitening and freckle removal activities.

[0047] Table 7: Tyrosinase inhibition rate and melanin synthesis inhibition rate

[0048]

[0049] Example 7 Lac·Phe and N-acetyltaurine have anti-fatigue effects

[0050] Kunming mice were randomly divided into a control group, a Lac-Phe group, and an N-acetyltaurine group, with 6 mice in each group. The control group and the model group were gavaged with 0.5% sodium carboxymethylcellulose (CMC-Na), and the other groups were gavaged with Lac-Phe (150 mg / kg) and N-acetyltaurine (150 mg / kg) for 3 consecutive days. On the third day, a weighted swimming test was performed on mice 1 hour after gavage. A rubber block weighing 7% of the body weight was tied to the tail of the test mouse, and the mice were placed in a water tank about 30 cm deep and at a water temperature of 20-24°C to swim. It was observed that the swimming range of the mice gradually decreased, the movement of the hind limbs gradually became slow, and they moved up and down between the water surface and the bottom of the water. The failure of the mouse head to float to the surface within 5 seconds of contact with the water surface was used as an indicator of fatigue, and the model was successfully replicated. During the test, the time for the mouse to swim to exhaustion was recorded. The results are shown in Table 8, which shows that Lac·Phe and N-acetyltaurine have good anti-fatigue activity.

[0051] Table 8: Animal weight-bearing swimming time

[0052]

Claims

1. Application of N-lactylphenylalanine (Lac-Phe) and N-acetyltaurine, or pharmaceutically acceptable salts thereof, in the preparation of medicines / health products for preventing and treating altitude sickness, hypoxemia, respiratory failure, alcoholism, drug-induced liver injury, hyperuricemia, gout, whitening and anti-freckle, and anti-fatigue. The structures of the N-lactylphenylalanine (Lac-Phe) and N-acetyltaurine are as follows:

2. The use according to claim 1, characterized in that: The altitude sickness includes altitude sickness, high altitude pulmonary edema and high altitude coma.

3. The use according to claim 1, characterized in that: The alcohol poisoning includes acute alcohol poisoning, chronic alcohol poisoning, alcoholic fatty liver disease and alcohol dependence.

4. The use according to claim 1, characterized in that: The drug-induced liver injury includes direct drug hepatotoxicity, idiosyncratic hepatotoxicity, and indirect hepatotoxicity-induced liver injury.

5. The use according to claim 1, characterized in that: The medicine further comprises a pharmaceutically acceptable carrier or excipient.

6. The use according to any one of claims 1 to 5, characterized in that: The medicine is an oral preparation, a skin external preparation or an injection preparation product.